Distribution of HLA-E and LMP-1 peptide variants in primary and reactivating EBV infections. (A-B) Distribution of HLA-E (A) and LMP-1 (B) variants in immunocompetent older patients with EBV reactivations (N = 28). (C-F) Distribution of HLA-E (C,D) and (E,F) LMP-1 (E,F) variants in immunosuppressed non-PTLD (N = 149) (C,E) and EBV⁺PTLD (N = 36) (D,F) transplant patients with EBV reactivations. (A,C,D) Fractions represent the relative frequency of HLA-E∗0101/0101, HLA-E∗0101/0103, and HLA-E∗0103/0103. (B,E,F) Fractions represent the relative frequency of the LMP-1 peptide GGDPHLPTL, GSDPHLPTL, GGDPHLPPL, GGDPPLPTL, GCDPHLPTL, GIDPHLPTL, GAGPHLPTL, GGDTPLPTL, GDDPHLPTL, GGDPHVPTL, and GTDPHLPTL variants. ⁺The frequency of the HLA-E genotypes was compared with the control cohort by the χ² test. ⁺⁺The frequency of the LMP-1 variants was compared with the adolescent/adult cohort with IM by the χ² test.